ESCMID is a proud member of the Guidelines International Network (GIN), a group advancing evidence-based practices with its international library containing around 4,000 guidance documents. The library is accessible through this link.
Discover the summary of our 2021 - 2026 guidelines, along with other guidelines endorsed by ESCMID.
|
Description |
Link to publication |
|---|---|
|
IDSA/ESCMID 2026 consensus statements on Staphylococcus aureus bacteremia: risk stratification, diagnostic evaluation, and management of adults and children (September 2026) |
|
|
ESCMID clinical guidelines on the evaluation and management of a reported antibiotic allergy (May 2026) |
|
|
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026 (endorsed by ESCMID) (Apr 2026) |
|
|
Management of COVID-19 in immunocompromised patients: an ESCMID consensus document (Oct 2025) |
|
|
IDSA 2025 guideline update on complicated urinary tract infections (endorsed by ESCMID) (July 2025) |
|
|
ESCMID/EUCIC clinical guidelines on preoperative decolonisation and targeted prophylaxis in patients colonised by multidrug-resistant Gram-positive bacteria before surgery (Dec 2024) |
|
|
ESCMID guidelines for antimicrobial stewardship in emergency departments (Nov 2024) |
|
|
IDSA 2024 guideline update on the risk assessment, diagnostic imaging, and microbiological evaluation of complicated intra-abdominal infections in adults, children, and pregnant people (Oct 2024) |
|
|
Rituals and behaviours in the operating theatre - joint guidelines of HIS and ESCMID (Feb 2024) |
|
|
ESCMID guidelines on diagnosis and treatment of brain abscess in children and adults (Jan 2024) |
|
|
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia (Jun 2023) |
|
|
ESCMID/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery (Apr 2023) |
|
|
ESCMID guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease (Dec 2022) |
|
|
ESCMID rapid guidelines for assessment and management of long COVID (Jul 2022) |
|
|
ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2 (Jun 2022) |
|
|
ESCMID guidelines on testing for SARS-CoV-2 in asymptomatic individuals to prevent transmission in the healthcare setting (May 2022) |
|
|
ESCMID guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by ESICM) (Apr 2022) |
|
|
ESCMID COVID-19 living guidelines: drug treatment and clinical management (Feb 2022) |
|
|
2021 update on the ESCMID treatment guidance document for Clostridioides difficile infection in adults (Dec 2021) |